NewLink could raise $60 million through at-the-market equity offering

Cantor Fitzgerald helps finance general corporate purposes, research

By Devika Patel

Knoxville, Tenn., Sept. 5 - NewLink Genetics Corp. negotiated a $60 million at-the-market offering with Cantor Fitzgerald & Co. on Sept. 5, according to a prospectus supplement and 8-K filed Thursday with the Securities and Exchange Commission.

Cantor will be paid a 3% commission.

Proceeds will be used for general corporate purposes, including regulatory, clinical trial, research and development, pre-commercial, general and administrative and manufacturing expenses.

The biopharmaceutical company is based in Ames, Iowa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.